Known Side Effects from Clinical Data
Lurbinectedin ( Zepzelca), approved for small cell lung cancer, shows mostly short-term hematologic toxicities like anemia, neutropenia, and thrombocytopenia in trials. Long-term data is limited due to the drug's recent approval (2020) and use in advanced disease with short survival.[1][2]
Myelosuppression and Bone Marrow Risks
Prolonged or repeated cycles can lead to cumulative bone marrow suppression. Patients may develop persistent cytopenias, increasing infection or bleeding risk over months. In the phase 2 trial (n=105), 40% had grade 3-4 neutropenia lasting beyond one cycle, with some requiring transfusions long-term.[2][3]
Fatigue and Neuromuscular Effects
Chronic fatigue affects up to 60% of patients, persisting post-treatment in survivors. Rare reports include peripheral neuropathy or myopathy from prior chemotherapy combinations, potentially worsening with lurbinectedin.[1][4]
Hepatic and Renal Concerns
Elevated liver enzymes occur in 20-30% of cases, with potential for ongoing hepatotoxicity in patients with metastases. Renal function declines noted in <10%, but monitoring is advised for long-term use.[2]
Secondary Malignancy Risk
As an alkylating-like agent, lurbinectedin may raise leukemia risk with extended exposure, similar to other chemotherapies. No trial data confirms this yet, but preclinical studies show DNA damage persistence.[3][5]
Patient Reports and Real-World Monitoring
Post-marketing surveillance flags ongoing fatigue, anemia, and rare pulmonary issues. Long-term survivors (rare in SCLC) report quality-of-life impacts; NCCN guidelines recommend indefinite blood count checks.[1][4]
Sources:
[1] FDA Label for Zepzelca
[2] Trigo et al., Lancet Oncology (2020)
[3] DrugPatentWatch.com - Lurbinectedin
[4] NCCN Guidelines for SCLC
[5] Paz-Ares et al., J Clin Oncol (2021)